The drug is ZMapp and is being jointly developed by Mapp and Defyrus.
The companies currently are exploring pathways to ramp production and test the drug in Ebola patients. “It’s absolutely overwhelming,” Larry Zeitlin, the president of Mapp, told The New York Times. “We are discussing with the [Food and Drug Administration] the right path to make the drug available to people as quickly and safely as possible.”